Shattuck Labs IncNASDAQ:STTK
- LAST PRICE3.6800
- TODAY'S CHANGE (%)-0.0200 (-0.5405%)
- Bid / Lots3.6000/ 1
- Ask / Lots3.8800/ 1
- Open / Previous Close3.7000 / 3.7000
- Day Range
- 52 Week Range
- Volume303,583
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | STTK |
|---|---|---|
| 09:32 ET | 2676 | 3.7 |
| 09:34 ET | 1111 | 3.685 |
| 09:38 ET | 350 | 3.69 |
| 09:39 ET | 355 | 3.68 |
| 09:41 ET | 100 | 3.66 |
| 09:43 ET | 600 | 3.68 |
| 09:45 ET | 150 | 3.6873 |
| 09:50 ET | 408 | 3.66 |
| 09:52 ET | 1844 | 3.64 |
| 09:59 ET | 200 | 3.64 |
| 10:01 ET | 100 | 3.645 |
| 10:03 ET | 1479 | 3.63 |
| 10:06 ET | 200 | 3.625 |
| 10:10 ET | 400 | 3.61 |
| 10:14 ET | 1471 | 3.63 |
| 10:15 ET | 100 | 3.639 |
| 10:17 ET | 1209 | 3.65 |
| 10:19 ET | 1281 | 3.65 |
| 10:21 ET | 100 | 3.62 |
| 10:30 ET | 381 | 3.611 |
| 10:33 ET | 481 | 3.62 |
| 10:37 ET | 9511 | 3.59 |
| 10:39 ET | 1659 | 3.61 |
| 10:42 ET | 950 | 3.6156 |
| 10:44 ET | 850 | 3.64 |
| 10:48 ET | 492 | 3.65 |
| 10:57 ET | 200 | 3.67 |
| 11:00 ET | 850 | 3.67 |
| 11:06 ET | 614 | 3.67 |
| 11:08 ET | 760 | 3.6891 |
| 11:09 ET | 200 | 3.685 |
| 11:15 ET | 100 | 3.685 |
| 11:22 ET | 991 | 3.65 |
| 11:27 ET | 540 | 3.64 |
| 11:29 ET | 300 | 3.63 |
| 11:45 ET | 200 | 3.64 |
| 11:47 ET | 200 | 3.645 |
| 11:51 ET | 300 | 3.655 |
| 11:54 ET | 440 | 3.65 |
| 11:58 ET | 300 | 3.64 |
| 12:00 ET | 1200 | 3.62 |
| 12:02 ET | 802 | 3.61 |
| 12:03 ET | 2011 | 3.62 |
| 12:05 ET | 200 | 3.61 |
| 12:07 ET | 572 | 3.61 |
| 12:12 ET | 765 | 3.63 |
| 12:16 ET | 810 | 3.635 |
| 12:18 ET | 3527 | 3.66 |
| 12:20 ET | 400 | 3.685 |
| 12:21 ET | 100 | 3.68 |
| 12:23 ET | 100 | 3.685 |
| 12:27 ET | 300 | 3.675 |
| 12:30 ET | 200 | 3.679 |
| 12:32 ET | 788 | 3.665 |
| 12:38 ET | 100 | 3.67 |
| 12:41 ET | 300 | 3.67 |
| 12:43 ET | 457 | 3.66 |
| 12:45 ET | 100 | 3.65 |
| 12:48 ET | 210 | 3.64 |
| 12:50 ET | 100 | 3.63 |
| 12:52 ET | 500 | 3.64 |
| 12:57 ET | 200 | 3.64 |
| 01:01 ET | 963 | 3.64 |
| 01:03 ET | 1476 | 3.65 |
| 01:06 ET | 786 | 3.67 |
| 01:08 ET | 100 | 3.67 |
| 01:14 ET | 937 | 3.685 |
| 01:15 ET | 376 | 3.67 |
| 01:17 ET | 300 | 3.68 |
| 01:19 ET | 1048 | 3.67 |
| 01:21 ET | 516 | 3.67 |
| 01:24 ET | 29568 | 3.63 |
| 01:26 ET | 1100 | 3.64 |
| 01:28 ET | 200 | 3.65 |
| 01:30 ET | 1053 | 3.65 |
| 01:33 ET | 1000 | 3.65 |
| 01:39 ET | 106 | 3.64 |
| 01:42 ET | 550 | 3.65 |
| 01:44 ET | 1482 | 3.65 |
| 01:46 ET | 300 | 3.65 |
| 01:55 ET | 2869 | 3.65 |
| 01:57 ET | 1278 | 3.665 |
| 02:00 ET | 200 | 3.665 |
| 02:06 ET | 2675 | 3.66 |
| 02:09 ET | 100 | 3.66 |
| 02:13 ET | 200 | 3.66 |
| 02:15 ET | 100 | 3.655 |
| 02:20 ET | 270 | 3.655 |
| 02:22 ET | 1001 | 3.64 |
| 02:24 ET | 100 | 3.645 |
| 02:27 ET | 100 | 3.65 |
| 02:31 ET | 100 | 3.645 |
| 02:33 ET | 400 | 3.645 |
| 02:36 ET | 100 | 3.645 |
| 02:40 ET | 6073 | 3.64 |
| 02:42 ET | 2100 | 3.65 |
| 02:44 ET | 200 | 3.65 |
| 02:47 ET | 1611 | 3.64 |
| 02:49 ET | 100 | 3.645 |
| 02:51 ET | 250 | 3.65 |
| 02:54 ET | 100 | 3.645 |
| 02:56 ET | 200 | 3.645 |
| 02:58 ET | 1732 | 3.655 |
| 03:00 ET | 300 | 3.655 |
| 03:02 ET | 200 | 3.655 |
| 03:03 ET | 2612 | 3.67 |
| 03:05 ET | 1466 | 3.69 |
| 03:07 ET | 600 | 3.68 |
| 03:09 ET | 4253 | 3.7 |
| 03:12 ET | 100 | 3.7 |
| 03:16 ET | 200 | 3.695 |
| 03:18 ET | 100 | 3.695 |
| 03:20 ET | 100 | 3.7 |
| 03:21 ET | 4891 | 3.69 |
| 03:23 ET | 100 | 3.69 |
| 03:25 ET | 200 | 3.69 |
| 03:27 ET | 300 | 3.69 |
| 03:30 ET | 853 | 3.69 |
| 03:32 ET | 300 | 3.69 |
| 03:34 ET | 1161 | 3.685 |
| 03:36 ET | 100 | 3.68 |
| 03:38 ET | 937 | 3.685 |
| 03:39 ET | 514 | 3.685 |
| 03:41 ET | 3313 | 3.69 |
| 03:43 ET | 100 | 3.695 |
| 03:45 ET | 1903 | 3.7 |
| 03:48 ET | 300 | 3.7 |
| 03:50 ET | 2164 | 3.695 |
| 03:52 ET | 3518 | 3.7 |
| 03:54 ET | 8931 | 3.7 |
| 03:56 ET | 10566 | 3.685 |
| 03:57 ET | 5165 | 3.67 |
| 03:59 ET | 9362 | 3.68 |
Jul 1, 2024
Shattuck Labs Announces Addition to Russell 2000(R) and Russell 3000(R) Indexes, from 6:00AM ET on Monday Jul 01, 2024 by Dow Jones
6:00AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 20, 2024
DJ Shattuck Labs Is Maintained at Buy by HC Wainwright & Co., from 6:32AM ET on Thursday Jun 20, 2024 by Dow Jones
6:32AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 17, 2024
DJ Shattuck Labs Is Maintained at Buy by Citigroup, from 11:04AM ET on Monday Jun 17, 2024 by Dow Jones
11:04AM ET on Monday Jun 17, 2024 by Dow Jones
Jun 14, 2024
DJ Shattuck Labs Is Maintained at Buy by Needham, from 12:01PM ET on Friday Jun 14, 2024 by Dow Jones
12:01PM ET on Friday Jun 14, 2024 by Dow JonesShattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients, from 6:00AM ET on Friday Jun 14, 2024 by Dow Jones
6:00AM ET on Friday Jun 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shattuck Labs Inc | 175.0M | -1.9x | --- |
XBiotech Inc | 173.6M | -5.6x | --- |
Abeona Therapeutics Inc | 186.0M | -1.4x | --- |
bluebird bio Inc | 175.8M | -1.2x | --- |
Design Therapeutics Inc | 193.2M | -3.3x | --- |
Immutep Ltd | 288.3M | -7.4x | --- |
Company Information
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Contact Information
- Headquarters
- 500 W. 5Th Street, Suite 100AUSTIN, TX, United States 78701
- Phone
- 512-900-4690
- Fax
- ---
Executives
- Independent Chairman of the Board
- George Golumbeski
- Chief Executive Officer, Co-Founder, Director
- Taylor Schreiber
- Chief Financial Officer
- Andrew Neill
- General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
- Stephen Stout
- Chief Business Officer
- Casi Deyoung
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $175.0M |
|---|---|
Revenue (TTM) | $2.7M |
Shares Outstanding | 47.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-1.93 |
Book Value | $3.06 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 64.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,327.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
